Arcus Biosciences (RCUS) Competitors

$24.99 -0.01 (-0.06%)

Closing price 03:59 PM Eastern

Extended Trading

$24.57 -0.42 (-1.66%)

As of 04:47 PM Eastern

RCUS vs. ELAN, AXSM, RDY, ARWR, and ABVX

Should you buy Arcus Biosciences stock or one of its competitors? MarketBeat compares Arcus Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Arcus Biosciences include Elanco Animal Health (ELAN), Axsome Therapeutics (AXSM), Dr. Reddy's Laboratories (RDY), Arrowhead Pharmaceuticals (ARWR), and Abivax (ABVX). These companies are all part of the "pharmaceutical products" industry.

How does Arcus Biosciences compare to Elanco Animal Health?

Arcus Biosciences (NYSE:RCUS) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.

Arcus Biosciences has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.69, indicating that its stock price is 69% more volatile than the broader market.

Elanco Animal Health has higher revenue and earnings than Arcus Biosciences. Elanco Animal Health is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcus Biosciences	$236M	13.32	-$353M	-$3.18	N/A
Elanco Animal Health	$4.89B	2.21	-$232M	-$0.50	N/A

Arcus Biosciences currently has a consensus target price of $33.33, suggesting a potential upside of 33.41%. Elanco Animal Health has a consensus target price of $28.20, suggesting a potential upside of 30.28%. Given Arcus Biosciences' higher possible upside, equities research analysts clearly believe Arcus Biosciences is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

Elanco Animal Health has a net margin of -4.95% compared to Arcus Biosciences' net margin of -156.36%. Elanco Animal Health's return on equity of 7.42% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcus Biosciences	-156.36%	-68.97%	-35.27%
Elanco Animal Health	-4.95%	7.42%	3.66%

In the previous week, Arcus Biosciences had 3 more articles in the media than Elanco Animal Health. MarketBeat recorded 16 mentions for Arcus Biosciences and 13 mentions for Elanco Animal Health. Elanco Animal Health's average media sentiment score of 0.41 beat Arcus Biosciences' score of 0.27 indicating that Elanco Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcus Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Elanco Animal Health	2 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

92.9% of Arcus Biosciences shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 9.6% of Arcus Biosciences shares are held by company insiders. Comparatively, 1.1% of Elanco Animal Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Elanco Animal Health beats Arcus Biosciences on 11 of the 16 factors compared between the two stocks.

How does Arcus Biosciences compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Arcus Biosciences (NYSE:RCUS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends.

Axsome Therapeutics has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market.

Axsome Therapeutics has higher revenue and earnings than Arcus Biosciences. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$708.24M	16.88	-$183.17M	-$3.73	N/A
Arcus Biosciences	$236M	13.32	-$353M	-$3.18	N/A

Axsome Therapeutics presently has a consensus target price of $251.26, indicating a potential upside of 8.18%. Arcus Biosciences has a consensus target price of $33.33, indicating a potential upside of 33.41%. Given Arcus Biosciences' higher possible upside, analysts clearly believe Arcus Biosciences is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

Axsome Therapeutics has a net margin of -26.59% compared to Arcus Biosciences' net margin of -156.36%. Arcus Biosciences' return on equity of -68.97% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
Arcus Biosciences	-156.36%	-68.97%	-35.27%

In the previous week, Arcus Biosciences had 8 more articles in the media than Axsome Therapeutics. MarketBeat recorded 16 mentions for Arcus Biosciences and 8 mentions for Axsome Therapeutics. Arcus Biosciences' average media sentiment score of 0.27 beat Axsome Therapeutics' score of -0.03 indicating that Arcus Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Arcus Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by insiders. Comparatively, 9.6% of Arcus Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Axsome Therapeutics and Arcus Biosciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Arcus Biosciences compare to Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories (NYSE:RDY) and Arcus Biosciences (NYSE:RCUS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends.

Dr. Reddy's Laboratories has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market.

3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Comparatively, 9.6% of Arcus Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Dr. Reddy's Laboratories has higher revenue and earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Reddy's Laboratories	$3.58B	3.15	$663M	$0.77	17.55
Arcus Biosciences	$236M	13.32	-$353M	-$3.18	N/A

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Arcus Biosciences' net margin of -156.36%. Dr. Reddy's Laboratories' return on equity of 12.28% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Reddy's Laboratories	12.90%	12.28%	8.25%
Arcus Biosciences	-156.36%	-68.97%	-35.27%

Dr. Reddy's Laboratories presently has a consensus target price of $16.90, indicating a potential upside of 25.09%. Arcus Biosciences has a consensus target price of $33.33, indicating a potential upside of 33.41%. Given Arcus Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Arcus Biosciences is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

In the previous week, Arcus Biosciences had 10 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 16 mentions for Arcus Biosciences and 6 mentions for Dr. Reddy's Laboratories. Arcus Biosciences' average media sentiment score of 0.27 beat Dr. Reddy's Laboratories' score of -0.47 indicating that Arcus Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dr. Reddy's Laboratories	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arcus Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Arcus Biosciences beats Dr. Reddy's Laboratories on 10 of the 17 factors compared between the two stocks.

How does Arcus Biosciences compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Arcus Biosciences (NYSE:RCUS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, media sentiment, valuation and dividends.

Arrowhead Pharmaceuticals has a beta of 1.28, indicating that its stock price is 28% more volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market.

62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are owned by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are owned by insiders. Comparatively, 9.6% of Arcus Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Arrowhead Pharmaceuticals has higher revenue and earnings than Arcus Biosciences. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	13.53	-$1.63M	-$2.15	N/A
Arcus Biosciences	$236M	13.32	-$353M	-$3.18	N/A

Arrowhead Pharmaceuticals has a net margin of -48.38% compared to Arcus Biosciences' net margin of -156.36%. Arrowhead Pharmaceuticals' return on equity of -55.09% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%
Arcus Biosciences	-156.36%	-68.97%	-35.27%

Arrowhead Pharmaceuticals presently has a consensus target price of $87.80, indicating a potential upside of 10.18%. Arcus Biosciences has a consensus target price of $33.33, indicating a potential upside of 33.41%. Given Arcus Biosciences' higher probable upside, analysts plainly believe Arcus Biosciences is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.83
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

In the previous week, Arrowhead Pharmaceuticals had 12 more articles in the media than Arcus Biosciences. MarketBeat recorded 28 mentions for Arrowhead Pharmaceuticals and 16 mentions for Arcus Biosciences. Arrowhead Pharmaceuticals' average media sentiment score of 0.81 beat Arcus Biosciences' score of 0.27 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	7 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcus Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Arrowhead Pharmaceuticals beats Arcus Biosciences on 12 of the 16 factors compared between the two stocks.

How does Arcus Biosciences compare to Abivax?

Abivax (NASDAQ:ABVX) and Arcus Biosciences (NYSE:RCUS) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, media sentiment, valuation and dividends.

Abivax has a net margin of 0.00% compared to Arcus Biosciences' net margin of -156.36%. Arcus Biosciences' return on equity of -68.97% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-146.43%	-88.69%
Arcus Biosciences	-156.36%	-68.97%	-35.27%

In the previous week, Arcus Biosciences had 11 more articles in the media than Abivax. MarketBeat recorded 16 mentions for Arcus Biosciences and 5 mentions for Abivax. Abivax's average media sentiment score of 1.14 beat Arcus Biosciences' score of 0.27 indicating that Abivax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcus Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Abivax presently has a consensus target price of $137.15, indicating a potential upside of 13.35%. Arcus Biosciences has a consensus target price of $33.33, indicating a potential upside of 33.41%. Given Arcus Biosciences' higher probable upside, analysts plainly believe Arcus Biosciences is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

47.9% of Abivax shares are owned by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are owned by institutional investors. 9.6% of Arcus Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Arcus Biosciences has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.37	N/A
Arcus Biosciences	$236M	13.32	-$353M	-$3.18	N/A

Abivax has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market.

Summary

Arcus Biosciences beats Abivax on 11 of the 15 factors compared between the two stocks.

Get Arcus Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RCUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RCUS vs. The Competition

Export

Metric	Arcus Biosciences	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$3.14B	$3.40B	$6.29B	$23.00B
Dividend Yield	N/A	2.31%	2.79%	4.07%
P/E Ratio	-7.86	18.81	20.87	28.39
Price / Sales	13.32	181.67	521.63	40.00
Price / Cash	N/A	122.51	42.94	25.11
Price / Book	5.99	6.74	9.86	4.76
Net Income	-$353M	$24.11M	$3.55B	$1.06B
7 Day Performance	0.74%	0.07%	-0.32%	-0.76%
1 Month Performance	8.63%	0.84%	1.34%	1.73%
1 Year Performance	191.89%	78.10%	41.03%	25.04%

Arcus Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RCUS Arcus Biosciences	3.346 of 5 stars	$24.99 -0.1%	$33.33 +33.4%	+188.9%	$3.14B	$236M	N/A	500	Analyst Forecast Insider Trade Gap Up
ELAN Elanco Animal Health	3.9171 of 5 stars	$21.67 -8.4%	$28.20 +30.1%	+67.2%	$11.81B	$4.72B	N/A	9,400	Analyst Downgrade
AXSM Axsome Therapeutics	2.338 of 5 stars	$216.47 -0.4%	$251.26 +16.1%	+122.7%	$11.19B	$638.50M	N/A	380
RDY Dr. Reddy's Laboratories	3.3264 of 5 stars	$13.15 -0.6%	$16.90 +28.6%	-7.9%	$11.04B	$3.81B	17.07	27,811	News Coverage Earnings Report Analyst Downgrade Gap Up
ARWR Arrowhead Pharmaceuticals	2.154 of 5 stars	$77.74 +6.9%	$84.90 +9.2%	+409.7%	$10.24B	$829.45M	N/A	400	Trending News Earnings Report Analyst Forecast Analyst Revision Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:RCUS) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arcus Biosciences (RCUS) Competitors

RCUS vs. ELAN, AXSM, RDY, ARWR, and ABVX

How does Arcus Biosciences compare to Elanco Animal Health?

Summary

How does Arcus Biosciences compare to Axsome Therapeutics?

Summary

How does Arcus Biosciences compare to Dr. Reddy's Laboratories?

Summary

How does Arcus Biosciences compare to Arrowhead Pharmaceuticals?

Summary

How does Arcus Biosciences compare to Abivax?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCUS vs. The Competition

Arcus Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Arcus Biosciences (RCUS) Competitors

RCUS vs. ELAN, AXSM, RDY, ARWR, and ABVX

How does Arcus Biosciences compare to Elanco Animal Health?

Which has more risk & volatility, RCUS or ELAN?

Which has stronger valuation & earnings, RCUS or ELAN?

Do analysts rate RCUS or ELAN?

Is RCUS or ELAN more profitable?

Does the media prefer RCUS or ELAN?

Do institutionals and insiders believe in RCUS or ELAN?

Summary

How does Arcus Biosciences compare to Axsome Therapeutics?

Which has more volatility & risk, AXSM or RCUS?

Which has preferable earnings and valuation, AXSM or RCUS?

Do analysts recommend AXSM or RCUS?

Is AXSM or RCUS more profitable?

Does the media favor AXSM or RCUS?

Do insiders & institutionals believe in AXSM or RCUS?

Summary

How does Arcus Biosciences compare to Dr. Reddy's Laboratories?

Which has more volatility & risk, RDY or RCUS?

Do insiders & institutionals believe in RDY or RCUS?

Which has preferable earnings and valuation, RDY or RCUS?

Is RDY or RCUS more profitable?

Do analysts recommend RDY or RCUS?

Does the media favor RDY or RCUS?

Summary

How does Arcus Biosciences compare to Arrowhead Pharmaceuticals?

Which has more risk & volatility, ARWR or RCUS?

Do institutionals & insiders believe in ARWR or RCUS?

Which has better earnings & valuation, ARWR or RCUS?

Is ARWR or RCUS more profitable?

Do analysts prefer ARWR or RCUS?

Does the media refer more to ARWR or RCUS?

Summary

How does Arcus Biosciences compare to Abivax?

Is ABVX or RCUS more profitable?

Does the media refer more to ABVX or RCUS?

Do analysts prefer ABVX or RCUS?

Do institutionals & insiders believe in ABVX or RCUS?

Which has better earnings & valuation, ABVX or RCUS?

Which has more risk & volatility, ABVX or RCUS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCUS vs. The Competition

Arcus Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools